doi: 10.1016/j.micinf.2005.07.017.
Epub 2005 Sep 29.
The rationale behind a vaccine based on multiple HIV antigens
Affiliations
- PMID: 16257558
- DOI: 10.1016/j.micinf.2005.07.017
Item in Clipboard
The rationale behind a vaccine based on multiple HIV antigens
Microbes Infect.
2005 Nov.
Free article
Abstract
The viral diversity of HIV-1 is likely to require a vaccine strategy that induces broad cellular and humoral anti-HIV-1 immunity. Our strategy is based on multiple HIV-1 DNA immunogens together with adjuvant recombinant granulocyte-macrophage stimulating factor. This article describes pre-clinical and clinical work preceding the initiation of clinical HIV-1 phase I/II trials.
Similar articles
-
Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.Viral Immunol. 2005;18(4):678-88. doi: 10.1089/vim.2005.18.678. Viral Immunol. 2005. PMID: 16359234
-
Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.Hum Gene Ther. 2001 Sep 1;12(13):1623-37. doi: 10.1089/10430340152528129. Hum Gene Ther. 2001. PMID: 11535166 Clinical Trial.
-
Criteria for selection of HIV vaccine candidates--general principles.Microbes Infect. 2005 Nov;7(14):1433-5. doi: 10.1016/j.micinf.2005.07.019. Epub 2005 Sep 15. Microbes Infect. 2005. PMID: 16213181
-
Intracellular antibodies (intrabodies) for gene therapy of infectious diseases.Annu Rev Microbiol. 1997;51:257-83. doi: 10.1146/annurev.micro.51.1.257. Annu Rev Microbiol. 1997. PMID: 9343351 Review.
-
Candidate HIV-1 Tat vaccine development: from basic science to clinical trials.AIDS. 2006 Nov 28;20(18):2245-61. doi: 10.1097/QAD.0b013e3280112cd1. AIDS. 2006. PMID: 17117011 Review. No abstract available.
Cited by
-
Frequent associations between CTL and T-Helper epitopes in HIV-1 genomes and implications for multi-epitope vaccine designs.BMC Microbiol. 2010 Aug 9;10:212. doi: 10.1186/1471-2180-10-212. BMC Microbiol. 2010. PMID: 20696039 Free PMC article.
-
New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.Expert Rev Vaccines. 2016 Aug;15(8):1015-27. doi: 10.1586/14760584.2016.1158108. Epub 2016 Mar 16. Expert Rev Vaccines. 2016. PMID: 26910195 Free PMC article. Review.
-
Fusion to Flaviviral Leader Peptide Targets HIV-1 Reverse Transcriptase for Secretion and Reduces Its Enzymatic Activity and Ability to Induce Oxidative Stress but Has No Major Effects on Its Immunogenic Performance in DNA-Immunized Mice.J Immunol Res. 2017;2017:7407136. doi: 10.1155/2017/7407136. Epub 2017 Jun 22. J Immunol Res. 2017. PMID: 28717654 Free PMC article.
-
Therapeutic immunization for HIV.Springer Semin Immunopathol. 2006 Nov;28(3):221-30. doi: 10.1007/s00281-006-0029-0. Epub 2006 Oct 10. Springer Semin Immunopathol. 2006. PMID: 17031650 Review.
-
Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine.Int Rev Immunol. 2009;28(1):49-68. doi: 10.1080/08830180802495605. Int Rev Immunol. 2009. PMID: 19241253 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
